Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…Abstract Number: 1214 • 2013 ACR/ARHP Annual Meeting
Resistant Or Recurrent Acute Pericarditis: A New Therapeutic Opportunity?
Background/Purpose: The treatment of recurrent pericarditis relies on aspirin and/or non-steroidal anti-inflammatory drugs, as well as colchicine. Corticosteroid therapy, which is offered in resistant forms,…Abstract Number: 1215 • 2013 ACR/ARHP Annual Meeting
Human Immunodeficiency Virus Infection and Fracture Risk-a Meta-analysis
Background/Purpose: Human Immunodeficiency Virus (HIV) infection is associated with development of osteoporosis and decreased bone mineral density. However, studies have been inconclusive in whether this…Abstract Number: 1216 • 2013 ACR/ARHP Annual Meeting
Risk Factors Associated With Fracture Occurrence Appear to Differ Between Distal Radius, Clinical Vertebral, and Hip Fractures in Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort…Abstract Number: 1217 • 2013 ACR/ARHP Annual Meeting
Determination Of Vitamin D Level Prior To The Initiation Of Bisphosphonate Therapy
Background/Purpose: Vitamin D deficiency is under-recognized and in 18-35% of patients who do not respond to bisphosphonates, concurrent use of vitamin D 1000 units daily…Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…Abstract Number: 1220 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Characteristics and Fracture Risk: A Population-Based Study
Background/Purpose: Women and men with rheumatoid arthritis [RA] are at increased risk for a fragility fracture [fx]. To help better target those in need of…Abstract Number: 1221 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperthyroidism On Bone Mineral Density At Different Sites- An Observational Case-Control Study
Background/Purpose: Hyperthyroidism has been described as a risk factor for poor bone health.1, 2 The FRAXTM tool has been used to identify the ten year…Abstract Number: 1223 • 2013 ACR/ARHP Annual Meeting
Monitoring Osteoporosis Therapy: Can FRAX Help To Assess Success Or Failure In Achieving Treatment Goals?
Background/Purpose: 1. To determine whether FRAX can be used for monitoring patients receiving osteoporosis therapy and its clinical implications 2. Study the correlation between the…Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…Abstract Number: 1225 • 2013 ACR/ARHP Annual Meeting
FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
Background/Purpose: The FRAX® tool has been developed by WHO to evaluate fracture (Fx) risk of patients. It is based on individual patient models that integrate…Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting
Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…Abstract Number: 1228 • 2013 ACR/ARHP Annual Meeting
Trabecular BONE Score In Rheumatoid Arthritis and Ankylosing Spondylitis and Changes During LONG TERM Treatment With TNFA Blocking Agents
Background/Purpose: Inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. Bone mass in RA and AS has been…Abstract Number: 1229 • 2013 ACR/ARHP Annual Meeting
A Before and After Comparison Of The Effects Of Monitoring On a Quality Indicator For glucocorticoid–induced Osteoporosis In a Japanese Hospital
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most devastating side effects of glucocorticoid use, leading to a substantially increased risk of fracture and disability…